Meanwhile, Vertex is in the process of rolling out its gene-editing therapy Casgevy, the first CRISPR therapy ever approved and one that serves as a functional cure for two rare blood disorders. The ...

Reacting to new unemployment data, the Dow Jones Industrial Average and other major stock indexes dropped Thursday. Two early movers on the stock market today were Nvidia and Tesla. Please watch the ...

This honor highlights the outstanding system compatibility and long-term reliability of Trinasolar’s Vertex N single-glass ...

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators for inflammatory diseases, today announced the appointment of two Directors to its Board: ...

GlobalData’s report assesses the drugs in the Bcl 2 Like Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Vertex scored high marks across the core areas of the HDI Support Center Certification ... HDI Support Center Certification ...

Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain ...

The companies now plan on starting this year another large study of their drug, dapirolizumab pegol, in the hopes that they can confirm its safety and effectiveness to drug regulators.

Discover Vertex Pharmaceuticals' groundbreaking patent for variant PD-1 polypeptides, enhancing immunomodulatory proteins for innovative cancer and immune therapies.

Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which ...

One notable example is a new cystic fibrosis therapy, which management believes could set a new treatment standard for the genetic disease. Vertex already dominates the cystic fibrosis drug market ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.